Get started
Author

Edmund Poon

Observed name: E. Poon
ORCID: 0000-0002-7274-8718
Observed ORCID: 0000-0002-7274-8718
OpenAlex ID: A5012838760
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
2014 · Simon J. Dovedi, Amy L. Adlard, et al. · Cancer Research · 1,344
PDF
Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
2015 · Ross Stewart, Michelle Morrow, et al. · Cancer Immunology Research · 419
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
2017 · Simon J. Dovedi, Eleanor J. Cheadle, et al. · Clinical Cancer Research · 386
PDF
Targeting CD73 in the tumor microenvironment with MEDI9447
2016 · Carl M. Hay, Erin Sult, et al. · OncoImmunology · 299
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
2017 · Edmund Poon, Stefanie Mullins, et al. · Journal for ImmunoTherapy of Cancer · 76
PDF
Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation
2022 · Marta Lopez-Pelaez, Lucy Young, et al. · OncoImmunology · 37
Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2′-Deoxycytidine
2011 · Mengyong Yan, Nourredine Himoudi, et al. · Cancer Immunology Immunotherapy · 33
T h1 cytokines are more effective than T h2 cytokines at licensing anti‐tumour functions in CD 40‐activated human macrophages in vitro
2013 · Nadia Luheshi, Gareth Davies, et al. · European Journal of Immunology · 30
A cell-engineered system to assess tumor cell sensitivity to CD8 + T cell-mediated cytotoxicity
2019 · Nadine Nelson, Marta Lopez-Pelaez, et al. · OncoImmunology · 24
Development of Cellular Immune Responses against PAX5, a Novel Target for Cancer Immunotherapy
2008 · Mengyong Yan, Nourredine Himoudi, et al. · Cancer Research · 19
Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1
2014 · T. Illidge, G. Lipowska-Bhalla, et al. · International Journal of Radiation Oncology*Biology*Physics · 12
Abstract 285: MEDI9447: enhancing anti-tumor immunity by targeting CD73 In the tumor microenvironment
2015 · Carl Hay, Erin Sult, et al. · Cancer Research · 10
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al. · Cancer Research Communications · 7
PDF
1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
2021 · K. Papadopoulos, T.A. Yap, et al. · Annals of Oncology · 4
PDF
The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
2014 · Simon Dovedi, Amy Adlard, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
Abstract 3820: Novel PD-1/GITRL bispecific fusion protein delivering concurrent T cell co-stimulation and checkpoint pathway inhibition
2018 · Simon J. Dovedi, Jonathan Seaman, et al. · Cancer Research · 3
Abstract 5034: The antitumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
2014 · Simon J. Dovedi, Graznya Lipowska-Bhalla, et al. · Cancer Research · 3
Data from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al. · 1
573 FS120, an OX40/CD137 tetravalent bispecific dual agonist antibody, synergistically increases the antitumor activity of anti-PD-1 in preclinical studies
2021 · Matthew Lakins, Wenjia Liao, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo
2014 · Ross Stewart, Edmund Poon, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Assessment of TWIST1 as an immunotherapeutic target of cancer
2011 · Edmund Poon · UCL Discovery (University College London) · 1
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2025 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2025 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2025 · Charlotte J. Imianowski, Paula Kuo, et al.
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
2024 · Charlotte J. Imianowski, Paula Kuo, et al.
Works count: 67
Citation count: 2,714
H-index: 11
I10-index: 12
Year
Topic
Type